

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number
WO 2020/234387 A1

(43) International Publication Date
26 November 2020 (26.11.2020)

(51) International Patent Classification:

A61K 38/17 (2006.01) *A61P 35/00* (2006.01)
A61K 38/20 (2006.01) *C07K 14/54* (2006.01)
A61K 39/395 (2006.01) *C07K 14/715* (2006.01)
A61P 31/00 (2006.01) *C07K 16/28* (2006.01)

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(21) International Application Number:

PCT/EP2020/064132

(22) International Filing Date:

20 May 2020 (20.05.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

19175436.5 20 May 2019 (20.05.2019) EP
19177064.3 28 May 2019 (28.05.2019) EP

(71) Applicant: **CYTUNE PHARMA** [FR/FR]; 3, Chemin du
Pressoir Chênaie, 44100 Nantes (FR).

(72) Inventors: **MOEBIUS, Ulrich**; Am Rain 7, 82131 Gaut-
ing-Unterbrunn (DE). **BÉCHARD, David**; Le Courtil
Lie-Dit L'Ornière, 44360 Saint-Etienne de Montluc (FR).
ADKINS, Irena; Vinorská 370, 25073 Prezletice (CZ).
PODZIMKOVÁ, Nada; Kosmonautu 6, 37701 Jindřichuv
Hradec (CZ).

(74) Agent: **MAIWALD PATENTANWALTS- UND
RECHTSANWALTSGESELLSCHAFT MBH**; BÜH-
LER Dirk, Elisenhof, Elisenstrasse 3, 80335 München
(DE).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: IL-2/IL-15R β AGONIST DOSING REGIMENS FOR TREATING CANCER OR INFECTIOUS DISEASES

(57) Abstract: The present invention provides pulsed cyclic administration regimes and pulsed administration regimes for inter-
leukin-2/interleukin-15 receptor β (IL-2/IL-15R β) agonists for treating or managing cancer or infectious diseases in human patients.
The administration regimes inter alia involve daily administration of IL-2/IL-15R β agonists on 2, 3 or 4 consecutive days followed
by days without administration.

WO 2020/234387 A1